k Presentation of NNOSE plus pancreatic early stage pancreatic cancer test November 17, 2022, Tokyo, Japan Eric di Luccio, CTO of Hirotsu Bioscience announces the company develops the pancreatic cancer screening test NNose plus Pancreas using users urine in Tokyo on Thursday, November 17, 2022. Hirotsu Bioscience developed the new cancer specific test using genetically modifying C. elegans nematodes which react to smell of urine of patients of pancreatic cancer. Photo by Yoshio TsunodaAFLO Editorial Stock Photo - Afloimages
Sign up
Login
All images
Presentation of  N NOSE plus pancreatic  early stage pancreatic cancer test November 17, 2022, Tokyo, Japan   Eric di Luccio, CTO of Hirotsu Bioscience announces the company develops the pancreatic cancer screening test  N Nose plus Pancreas  using user s urine in Tokyo on Thursday, November 17, 2022. Hirotsu Bioscience developed the new cancer specific test using genetically modifying C. elegans nematodes which react to smell of urine of patients of pancreatic cancer.     Photo by Yoshio Tsunoda AFLO
ED

Presentation of "N-NOSE plus pancreatic" early stage pancreatic cancer test

November 17, 2022, Tokyo, Japan - Eric di Luccio, CTO of Hirotsu Bioscience announces the company develops the pancreatic cancer screening test "N-Nose plus Pancreas" using user's urine in Tokyo on Thursday, November 17, 2022. Hirotsu Bioscience developed the new cancer specific test using genetically modifying C. elegans nematodes which react to smell of urine of patients of pancreatic cancer. (Photo by Yoshio Tsunoda/AFLO)

Details

ID
204032846

Collection

License type
Editorial

Creation date
17-11-2022

Contact Aflo for all commercial uses.


Sign in
Member access
Login not found.